免责声明: 本站汇总 FDA、ClinicalTrials.gov、PubMed、SEC EDGAR 等官方公开数据,仅供一般参考,不构成医疗建议、诊断、治疗建议或投资建议。

临床试验

Phase 1/2a Study of ANPD001 in Parkinson Disease

NCT:NCT06344026 · ENROLLING_BY_INVITATION

NCT编号NCT06344026
状态ENROLLING_BY_INVITATION
开始日期2024-01-23
完成时间2030-04-30
SponsorAspen Neuroscience (INDUSTRY)
First posted
Last updated

简要摘要

This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease. All participants will have ANPD001 cells manufactured from their own previously collected cells.

官方来源

在 ClinicalTrials.gov 上查看 →

数据来自 ClinicalTrials.gov API。有关最新状态,请参阅官方记录。

↑